IL1B and diabetic cardiomyopathy: Interestingly, in T1DM-induced diabetic cardiomyopathy, administration of an anti-TNF-α monoclonal antibody lessen cardiac TNF-α and IL-1β expression in correlation with cardiac collagen-I and -III content, and improvement of left-ventricle function (Westermann et al., 2007).